advertising_left.gif     advertising_right.gif
"The Pink Sheet"
"The Tan Sheet"
Health News Daily


Allergenic Products
Anesthetic and Life Support Drugs
Anti-Infective Drugs
   Pediatric Subcommittee
Antiviral Drugs
   Immunosuppressive Drugs
Arthritis Drugs
Biological Response Modifiers
Blood Products
Cardiovascular and Renal Drugs
Dermatologic and Ophthalmic Drugs
Device Panels
Drug Safety and Risk Mgmt
   Drug Abuse
Endocrinologic and Metabolic Drugs
Gastrointestinal Drugs
Medical Imaging Drugs
Nonprescription Drugs
Oncologic Drugs
   Ethics Subcmte.
Peripheral and Central Nervous System Drugs
Pharmaceutical Science
   Nonclinical Studies
   Clinical Pharmacology
   Orally Inhaled & Nasal Drug Products
Pharmacy Compounding
Psychopharmacologic Drugs
Public Meetings
Pulmonary-Allergy Drugs
Reproductive Health Drugs
Science Board
Transmissible Spongiform Encephalopathies
Vaccines and Related Biological Products

Antidepressant Suicidality: Potential Class Risk Will Be Considered By Pediatric, Psychopharm Cmtes.

FDA will ask its Psychopharmacologic Drugs and Pediatric Advisory Committees to determine if there is an antidepressant class risk for suicidality based on agency analysis.

Draft questions for the Sept. 13-14 joint meeting include, ?do the suicidality data from these trials support the conclusion that any or all of these drugs increase the risk of suicidality in pediatric patients?? an Aug. 20 FDA Talk Paper states.

?Please discuss, for example, whether the increased risk applies to all antidepressants, only certain classes of antidepressants, or only certain antidepressants.?

FDA is convening the committees to review an agency meta-analysis, co-developed by Columbia University, of the association of antidepressants and pediatric suicidality.

Results showed a statistically significant link between suicidality and pediatric antidepressant drug use. However, the data also found a decrease (from 1.89 to 1.78) in overall suicidality risk.

Further analyses using the Columbia data set should be conducted to examine discontinuation-related events and events resulting in psychiatric inpatient hospitalization, an FDA epidemiologist recommended in an Aug. 16 memo.

FDA is also interested in the agency?s definitions of suicidality in the previous analyses. FDA is asking the committees to comment on FDA?s ?approach to classification of the possible cases of suicidality? and resulting analyses.

The Aug. 20 Talk Paper suggests FDA?s analyses could result in label changes for antidepressants: ?Although specific new labeling language has yet to be developed, FDA will assure that the labels of the antidepressants used in pediatric patients reflect the most recent information obtained from these studies and analyses.?

Lilly and Pfizer have submitted briefing documents for the meeting. Analyses of Prozac pediatric data, submitted to FDA in 2003, ?do not support an association of suicide-related events with fluoxetine treatment compared with placebo treatment in pediatric patients,? Lilly's briefing documents state. Pfizer analyses of Zoloft pediatric studies drew similar conclusions.

The Sept. 13-14 meeting serves as a follow-up to a Feb. 2 meeting during which advisory committee members expressed concern about the high degree of variability and lack of categorization of events believed to be suicide related. The Pediatric Ethics Subcommittee will meet Sept. 10 to discuss a study protocol for dextroamphetamine; a full committee review will follow Sept. 15.

To watch a webcast of this meeting, click the button below. To arrange for live videoconferencing, or to order videotapes & DVDs, email or call 800-627-8171.

Posted: Thursday, August 26, 2004

Sign up to view this meeting.
This meeting will be held September 13, 2004 at the Holiday Inn in Bethesda, Md. beginning at 8 a.m.
    Briefing Material                    

  • FDA Analysis Of Antidepressant Pediatric Suicidality Data To Be Reviewed Sept. 13-14   [Posted: 8/3/04]

    The latest FDA Advisory Committee news and information delivered directly to your email box.


    Copyright and Privacy Policy